logo
Fondation Santé
                 

BOARD OF DIRECTORS

Fulla Chapple | Executive Director

Ms. Fulla Chapple is the Executive Director of Fondation Santé. She joined the foundation in 2001 and is responsible for institutional development and coordinating the foundation's programs and projects.

Ms. Chapple has extensive experience in working for non-profit organizations in various capacities. Before joining Fondation Santé she served as the Fund Raising Consultant for UNHCR (United Nations High Commissioner for Refugees - Athens Branch Office). For several years she served as the Head of Fundraising and Communications for the Greek office of the World Wide Fund for Nature (WWF Greece). She also worked for Emporiki Venture Capital, where she was responsible for the management and administration of the company's regional offices in Eastern Europe and the Balkans.

Ms. Chapple began her career in London as a Conference Manager at The Conference Associates Ltd., and then as the owner and director of the Athens Conference Center, in Greece, which she managed for 15 years. Ms. Chapple holds a B.Sc. in business administration from Deree, The American College of Greece.

Fulla Chapple
Stelios Papadopoulos, Ph.D. | Chairman of the Board and Treasurer

Dr. Stelios Papadopoulos' career in biotech spans nearly three decades. Dr. Papadopoulos retired as Vice Chairman of Cowen & Co., LLC in August 2006 after six years with the firm where as an investment banker he focused on the biotech and pharma sectors. Prior to joining Cowen, he spent 13 years as an investment banker at PaineWebber, Incorporated where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in April 1987 from Drexel Burnham Lambert where he was a Vice President in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was a biotechnology analyst at Donaldson, Lufkin & Jenrette.

Dr. Stelios Papadopoulos is a co-founder and Chairman of the Board of Exelixis, Inc., and a member of the Board of Directors of Biogen Idec, Inc., BG Medicine, Inc., Regulus Therapeutics, Inc. and Joule Unlimited, Inc. He was also a co-founder and member of the Board of both, Anadys Pharmaceuticals, Inc. (acquired by Hoffman – La Roche in 2011) and Cellzome, Inc. (acquired by GlaxoSmithKline in 2012). In the not-for-profit sector, Dr. Papadopoulos is a co-founder and Chairman of Fondation Santé and a member of the Board of Visitors of Duke University Medical Center.

Prior to his business career, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. He continues his affiliation with NYU Medical Center as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos holds an M.S. in physics, a Ph.D. in biophysics and an M.B.A. in finance, all from New York University.

Stelios Papadopoulos
Spyros Artavanis-Tsakonas, Ph.D. | President

Spyros Artavanis-Tsakonas’ laboratory at the Harvard Medical School has been focused for many years on the use of model organisms to define critical targets and pathways important in development and disease. The identification and elucidation of much of the biology of the Notch pathway traces back to his laboratory. In the past few years his work has been and is focused on the identification and analysis of pathways involved in neurodegeneration.

From 2012 to March 2017 he was the Chief Scientific Officer for Biogen. He is now Professor Emeritus in the Department of Cell Biology which he joined originally in 1998 and was the founding Director of the Developmental and Regenerative Biology Program at Harvard Medical School. From 1999-2007 he was also the Isselbacher-Schwartz Professor, Massachusetts General Hospital Cancer Center.

Dr. Artavanis-Tsakonas' previous positions include: Professor, Collège de France, holding the Chair of Biology and Genetics of Development from 1999-2012; Professor, Department of Biology, Yale University; Professor, Department of Cell Biology, Yale University School of Medicine and Director of the Biological Sciences Division at Yale; he was a Howard Hughes Medical Institute Investigator from 1981 to 1998 when he left for Harvard. He is the Founding Director of The Department of Genetics and Developmental Biology at Institute Curie, Paris, 2007-2009.

Dr. Artavanis-Tsakonas obtained his M.A. in Chemistry from Eidgenoessische Technische Hochschule (ETH), Zurich, and his Ph.D. in Molecular Biology from Cambridge University at the MRC Laboratory of Molecular Biology. He did his postdoctoral research at Biozentrum, University of Basel, and Stanford University. In addition to his academic credentials, Dr. Artavanis-Tsakonas is a co-founder of Exelixis, Cellzome, and Anadys, and the philanthropic organization Fondation Santé.

Spyros Artavanis-Tsakonas
George A. Scangos, Ph.D. | Vice Chairman

George Scangos is the chief executive officer and a member of the Board of Directors of VIR. Previously, he was the chief executive officer and a member of the board of directors of Biogen since July 2010. From 1996 to July 2010, Dr. Scangos served as the president and chief executive officer of Exelixis, Inc., a drug discovery and development company, where he continues to serve on the board. From 1993 to 1996, Dr. Scangos served as president of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer’s biological products. Before joining Bayer in 1987, Dr. Scangos was a professor of biology at Johns Hopkins University, where he is still an adjunct professor. Dr. Scangos served as non-executive chairman of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2005 to July 2010 and was a director of the company from 2003 to July 2010. He currently serves on the Boards of Directors of Agilent, Exelixis, and Decibel Therapeutics.

Dr. Scangos served as the Chair of PhRMA from March of 2016 to January of 2017. He also served as the chair of the California Healthcare Institute in 2010 and was a member of the board of the Global Alliance for TB Drug Development until 2010. He is a member of the boards of trustees of the Boston Museum of Science and the Biomedical Science Careers Program, and a member of the National Board of Visitors of the University of California, Davis School of Medicine.

Dr. Scangos received a B.A. in Biology from Cornell University, and a Ph.D. from the University of Massachusetts. He was a Jane Coffin Childs Post-Doctoral Fellow in the laboratory of Dr. Frank Ruddle at Yale University.

George Scangos
Cheryl K. Lawton, Esq. | Vice President and Secretary

Ms. Cheryl Lawton has been a principal at c2venture, LLC since 2000. Ms. Lawton provides formation, management, operational, and legal consulting services to companies in the fields of biotechnology and life sciences. During the companies’ start-up phases she served as Senior Vice President, General Counsel and Secretary of Cellzome, Inc. (acquired by GlaxoSmithKline in 2012) and Senior Vice President of Operations at Anadys Pharmaceuticals, Inc. (acquired by Hoffman-La Roche in 2011).

Ms. Lawton has also worked with Archemix, Argose, and a subsidiary of Exelixis.
Prior to c2venture, Ms. Lawton served as Vice President of Administration, General Counsel and Secretary at Creative BioMolecules, Inc. from 1997 - 2000, and Vice President, General Counsel and Secretary at MediSense, Inc. from 1993 - 1997. Prior to MediSense, Ms. Lawton served as the director of legal services and operations at several healthcare companies. She has extensive experience in finance, contracts, intellectual property, operations, reorganization, and technology transfer and acquisitions.

Ms. Lawton received her J.D. from Suffolk University Law School and her B.A. from Lehigh University

Cheryl Lawton

MEMBERS

Katerina Artavanis-Tsakonas, Ph.D.

Dr Katerina Artavanis-Tsakonas is a Lecturer in Parasitology in the Department of Pathology at the University of Cambridge. Her laboratory studies the interaction between host and pathogen, specifically looking at intracellular parasites and what their tissue adaptations can reveal about host cell biology.

She established her laboratory at Imperial College London as a Wellcome Trust Fellow from 2009-2015. Prior to her fellowship, she had her post-doctoral training at Harvard and at the Whitehead Institute, MIT. Dr. Artavanis-Tsakonas received a BA in Fine Arts from Yale University in 1996, an MPH in Infectious Disease Epidemiology from Yale School of Medicine in 1998 and a PhD in Immunology from the London School of Hygiene & Tropical Medicine in 2003.

She has also served as an Assistant Vice President in the Equity Research Department of PaineWebber Inc.

Jason Fisherman, M.D.

Dr. Jason Fisherman joined Advent in 1994. Prior to Advent, Dr. Fisherman was senior director of medical research at Enzon, where he managed clinical programs in oncology, genetic diseases and blood substitutes. Previously, at the National Cancer Institute, he was responsible for developing a portfolio of anticancer drugs, including Taxol. While a research fellow at Dana Farber Cancer Institute, he focused on the regulation of gene transcription and molecular oncology.

Dr. Fisherman has led or co-led Advent's investments in over 20 companies, including Achillion Pharmaceuticals, Anadys Pharmaceuticals, Array BioPharma (Nasdaq: ARRY), Cellzome, Crucell (Nasdaq: CRXL; Euronext), Cubist Pharmaceuticals (Nasdaq: CBST), CV Therapeutics (Nasdaq: CVTX), deCODE genetics (Nasdaq: DCGN), EPIX Medical (Nasdaq: EPIX), Exelixis (Nasdaq: EXEL), ILEX Oncology (Nasdaq: IXLO), Neurogenetics, Oridion Systems (NSWX: ORIDN) and Telik (Nasdaq: TELK).

He received a BA in molecular biophysics and biochemistry from Yale, an MD from the University of Pennsylvania and an MBA from the Wharton School of the University of Pennsylvania. He is board certified in internal medicine and medical oncology.

Dr. Fisherman is currently a member of the board of directors of Achillion Pharmaceuticals, Inc., Anadys Pharmaceuticals, Inc., Cellzome, Inc., Exelixis, Inc., ILEX Oncology, Inc., Neurogenetics, Inc., and Oridion Systems Ltd.

Jean-François Formela, M.D.

Dr. Jean-François Formela focuses on new advances in biology and drug discovery technologies as well as novel therapeutics.

He is chair of the board of IFM Therapeutics and KDAC Therapeutics, and serves on the boards of F-star, Intellia Therapeutics (NASDAQ: NTLA), Kyn Therapeutics, Navitor, RaNA Therapeutics which he co-founded, and Spero Therapeutics.

Dr. Formela has been involved in the formation of companies such as Adnexus (acquired by BMS), ArQule (NASDAQ: ARQL), Arteaus Therapeutics (acquired by Lilly), Cellzome (acquired by GSK), deCODE (NASDAQ: DCGN, acquired by Amgen), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM) and SGX Pharmaceuticals (NASDAQ: SGXP, acquired by Lilly). He was also an investor in Achillion (NASDAQ: ACHN), Annovation Biopharma (acquired by The Medicines Company), CoStim Pharmaceuticals (acquired by Novartis) and Horizon Pharma (NASDAQ: HZNP) as well as a board member of Biochem Pharma (NASDAQ: BCHE, acquired by Shire) and Novexel (acquired by AstraZeneca).

Dr. Formela joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Prior to joining Atlas, he worked at Schering-Plough, where he directed U.S. Phase IV studies in all therapeutic areas. Before that, he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. Dr. Formela began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris. He is a member of the Massachusetts General Hospital Research Advisory Council and a former trustee of the Boston Institute of Contemporary Art.

Mark Kessel, Esq.

Mr. Kessel co-founded Symphony Capital, a private equity firm investing in the clinical development programs of biopharmaceutical companies. He is widely recognized as the leader in structuring product development investments for the biopharmaceutical industry. Mr. Kessel was formerly the Managing Partner of Shearman & Sterling, with day-to-day operating responsibility for one of the largest international law firms. He received a B.A. degree with honors in Economics from the City College of New York and a J.D. degree magna cum laude from Syracuse University College of Law.

Mr. Kessel is a director of Dynavax Technologies Corporation, the Foundation for Innovative New Diagnostics and Fondation Santé. He also served as a director of the Biotechnology Industry Organization, the Global Alliance for TB Drug Development, OXiGENE, Inc., Antigenics, Inc., Heller Financial Inc. and Harrods (UK) Limited and as a Trustee of the Museum of the City of New York.

Esperanza B. Papadopoulos, M.D.

Dr. Esperanza Papadopoulos is an Associate Member in the Department of Medicine at Memorial Sloan Kettering Cancer Center and an Associate Professor at the Cornell University Weill College of Medicine. Dr. Papadopoulos joined MSKCC in 1989 and since that time her research and clinical practice have been focused on allogeneic bone marrow transplantation. Specifically, her research interests relate to the use of adoptive cell therapy for treatment of post-transplant relapse and complications associated with viral infections.

Prior to MSKCC Dr. Papadopoulos was a Hematology-Oncology Fellow at New York University Medical Center. Dr. Papadopoulos received her medical degree form New York University School of Medicine in 1982 and continued at NYU as an intern, resident and chief resident in Internal Medicine. Dr. Papadopoulos is board certified in Internal Medicine, Hematology and Oncology.

Dr. Papadopoulos is a founding member of Fondation Santé.